Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 683 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Dermatitis (Eczema) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Molecular and Cellular Characterization of Spongiotic Dermatitis

NCT00371163
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis, Contact Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04562116
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab, CYP 450 Substrates
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 6, 2026, 10:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 6, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05999799
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Canoga Park, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

NCT04313400
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2
Drug
Lead sponsor
Amytrx Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Cerritos, California • Encino, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 3 Interventional

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT03422822
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional Results available

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

NCT01375205
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Cetaphil Restoraderm, Standard of Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Day to 3 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

NCT04392154
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
160
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 4 Interventional

A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis

NCT00666302
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
tacrolimus ointment, pimecrolimus cream
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
16 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 6, 2026, 10:54 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

NCT02680405
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin Biopsy, Skin tape stripping, Blood draw
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of CEE321 in Adult Subjects

NCT04612062
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CEE321
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03394677
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% ointment, Vehicle ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Los Angeles, California • Oklahoma City, Oklahoma • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 4 Interventional

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 6, 2026, 10:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Forward Access to Clinical and Technological Research: Genetic Influences on Cancer and Atopic Dermatitis

NCT04362852
View directory record Official record
Conditions
Eczema/Atopic Dermatitis, Cancer
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 6, 2026, 10:54 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07690371
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Results available

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

NCT05450198
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
MK-6194, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

NCT01064947
View directory record Official record
Conditions
Atopic Dermatitis, Secondary Infection
Interventions
Retapamulin 1%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
2 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT04195698
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
33
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294 Capsule
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Louisville, Kentucky • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

NCT00723489
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Live Yellow Fever Vaccine (YFV-17D), YFV-17D Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years to 43 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 6, 2026, 10:54 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

NCT07765888
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Northridge, California • Panama City, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 6, 2026, 10:54 AM EDT